Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We have upgraded our long-term recommendation on HSBC Holdings plc ( HBC - Analyst Report ) to Neutral from Underperform, based on the success of its restructuring initiatives. The company remains on track to achieve cost savings of $3.5 billion by 2013 and streamline its operations as well as improve its top line.
However, for the first quarter of 2012, HSBC reported an approximate 34% drop in net income attributable to lower fee and dividend income. These were partially offset by increases in the net interest income and net trading fees. Moreover, we remain concerned regarding the negative impact of the deepening Euro-zone crisis, weak revenue growth in its mature markets and regulatory restrictions on the company’s financials.
Last year, HSBC announced its plans of restructuring the business with the primary intention of increasing focus on the fast-growing and profitable markets. As of May 17, the company announced the divestiture or closure of 28 of its businesses.
Some of the major divestitures completed recently include the sale of U.S. credit card business to Capital One Financial Corporation ( COF - Analyst Report ) and 195 branches to First Niagara Bank, N.A., a unit of First Niagara Financial Group Inc. ( FNFG - Snapshot Report ) .
Additionally, HSBC’s brand, capital strength and extensive global network enables it to attract and retain clients. In an effort to further enhance its competitive advantage, the company is trying to increase its emerging-market exposure. The company has also been taking advantage of higher-growth, lower-cost regions such as China and India, to set up major back-office operations, which are likely to boost the bottom line.
Also, continuously improving profitability ratios are a major positive for HSBC. In addition to that, the company has been able to remain profitable during the financial crisis, a time when many financial institutions suffered. In 2011, return on average equity and return on risk-weighted assets increased to 10.9% and 1.9%, respectively, from 9.5% and 1.7% in the previous year.
On the flip side, though HSBC has been reporting stable operating income over the last several quarters, growth in core business performance indicators, including net interest income and fee income has been unsatisfactory. We believe that it would be difficult for the company to sustain in a sluggish economy coupled with low interest rate environment and increased regulations.
Further, despite management’s efforts to lower costs, we believe that rising wage inflation in faster-growing markets and strategic investments will not allow HSBC to make the cost line favorable any time soon.
In the first quarter of 2012, though the underlying cost efficiency ratio improved to 55.5% from 58.7% in the prior-year quarter, it still remained substantially higher than the company’s target range of 48–52%. We expect that the re-engineering efforts undertaken by the company to lower costs, will take some time.
HSBC currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Analyst Report on HBC
Read the full Analyst Report on COF
Read the full Snapshot Report on FNFG